دورية أكاديمية

Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts.

التفاصيل البيبلوغرافية
العنوان: Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts.
المؤلفون: Sturtzel, C., Grissenberger, S., Bozatzi, P., Scheuringer, E., Wenninger-Weinzierl, A., Zajec, Z., Dernovšek, J., Pascoal, S., Gehl, V., Kutsch, A., Granig, A., Rifatbegovic, F., Carre, M., Lang, A., Valtingojer, I., Moll, J., Lötsch, D., Erhart, F., Widhalm, G., Surdez, D.
المصدر: NPJ Precision Oncology; 5/18/2023, Vol. 7 Issue 1, p1-16, 16p
مصطلحات موضوعية: XENOGRAFTS, BRACHYDANIO, PHENOTYPES, XENOTRANSPLANTATION, DRUGS
مستخلص: Zebrafish xenotransplantation models are increasingly applied for phenotypic drug screening to identify small compounds for precision oncology. Larval zebrafish xenografts offer the opportunity to perform drug screens at high-throughput in a complex in vivo environment. However, the full potential of the larval zebrafish xenograft model has not yet been realized and several steps of the drug screening workflow still await automation to increase throughput. Here, we present a robust workflow for drug screening in zebrafish xenografts using high-content imaging. We established embedding methods for high-content imaging of xenografts in 96-well format over consecutive days. In addition, we provide strategies for automated imaging and analysis of zebrafish xenografts including automated tumor cell detection and tumor size analysis over time. We also compared commonly used injection sites and cell labeling dyes and show specific site requirements for tumor cells from different entities. We demonstrate that our setup allows us to investigate proliferation and response to small compounds in several zebrafish xenografts ranging from pediatric sarcomas and neuroblastoma to glioblastoma and leukemia. This fast and cost-efficient assay enables the quantification of anti-tumor efficacy of small compounds in large cohorts of a vertebrate model system in vivo. Our assay may aid in prioritizing compounds or compound combinations for further preclinical and clinical investigations. [ABSTRACT FROM AUTHOR]
Copyright of NPJ Precision Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:2397768X
DOI:10.1038/s41698-023-00386-9